Cita APA

Nowak, A. K., Ellingsen, E. B., Farooqi, S. J., Bjaanæs, M. M., Horndalsveen, H., Cedres Perez, S., & Haakensen, V. D. (2021). NIPU: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Citación estilo Chicago

Nowak, Anna K., Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Susana Cedres Perez, y Vilde Drageset Haakensen. NIPU: A Randomised, Open-label, Phase II Study Evaluating Nivolumab and Ipilimumab Combined With UV1 Vaccination As Second Line Treatment in Patients With Malignant Mesothelioma. 2021.

Cita MLA

Nowak, Anna K., et al. NIPU: A Randomised, Open-label, Phase II Study Evaluating Nivolumab and Ipilimumab Combined With UV1 Vaccination As Second Line Treatment in Patients With Malignant Mesothelioma. 2021.